Bridge Reinvention
A Bridge From Rehabilitation to Real-World: Re-Inventing Yourself After SCI
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Craig Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of SCI at any level;
- completed initial inpatient rehabilitation but are no more than 6 months post-discharge;
- 18 years of age or older at the time of study enrollment;
- English speaking in order to complete study measures and participate in group interactions; and
- able to provide informed consent to participate.
Exclusion Criteria:
- History of moderate or severe traumatic brain injury;
- current participation in another RCT;
- live beyond a reasonable commuting distance from Craig Hospital;
- unable to verbally communicate;
- unable to attend group sessions;
- active participation in another formal clinical group or psychological therapy;
- are currently experiencing severe depression which would require more intense treatment than is provided in this intervention, as evidenced by a score of 20 or higher on the Personal Health Questionnaire-9;
- report any current suicidal ideation on the Personal Health Questionnaire-9; or
- have any condition that, in the judgment of the investigators, precludes successful participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment
Re-Inventing Yourself after SCI protocol - 6-week educational sessions
|
6-week, manualized, cognitive-behaviorally based group educational intervention
|
|
No Intervention: Control
No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Moorong Self-Efficacy Scale (MSES)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The MSES is a 16 item self-report measure of self-efficacy related to everyday life activities, designed specifically for persons with SCI.
Individuals use a 7-point Likert scale ranging from 1 (very uncertain) to 7 (very certain) to rate their ability to perform 16 everyday tasks, with higher scores representing greater perceived self-efficacy.
A Total Score, ranging from 16 to 112 is calculated by summing all item responses.
The MSES has been used in previous studies of SCI, and demonstrates excellent internal consistency (alpha = 0.91 - 0.93), high reliability, and good convergent, concurrent and divergent validity.
Time to administer: 5 to 10 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Generalized Self-Efficacy Scale (GSES)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The GSES is a questionnaire designed to assess a person's ability to cope with a variety of difficult demands in life, with ten items scored using a Likert rating scale, ranging from 1 (not at all true) to 4 (exactly true).
This scale has acceptable internal reliability (ranging from.73 to .90) and criterion validity, as demonstrated by positive correlations with positive emotions, optimism, and work satisfaction, and negative correlations with anxiety, stress, depression, and health complaints.
The GSES has been used and validated in numerous populations and cultures, including people with SCI.
This self-administered scale produces a Total Score ranging from 10-40, with higher scores indicating greater general self-efficacy.
Time to administer: 3 to 5 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
|
Change in Satisfaction with Life Scale (SWLS)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The SWLS is a five item measure on which respondents rate their life satisfaction using a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree).
A Total Score is calculated by summing each of the items, having a range of 5 to 35, with higher scores representing greater perceived quality of life.
This measure has well established psychometric properties, with high reliability (.79 to .89),
good content validity, criterion validity, and has been extensively used in research regarding people with SCI.
Time to administer: 1 to 3 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
|
Change in Participation Assessment with Recombined Tools - Objective (PART-O)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The PART-O is a 17-item assessment of participation and has demonstrated good psychometric properties in measuring participation for people living with disabilities.
The PART-O has acceptable reliability and validity for persons with SCI.
An Averaged Total Score is computed by taking the mean of 17 items, with scores ranging from 0 (never participate in these types of activities) to 5 (almost always participate in these types of activities), with higher scores representing greater participation.
This assessment will be utilized to measure overall participation.
Time to administer: 8 to 10 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
|
Patient Health Questionnaire - 9 (PHQ-9)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The PHQ-9 is a 9 item scale that will be used to assess depression.
Respondents rate the frequency at which specific problems have been bothersome during the past two weeks, using a four point scale ranging from 0 (not at all) to 3 (nearly every day).
A total score is calculated by summing all items, with higher scores indicating an increasing severity of depression.
This scale demonstrates excellent psychometrics, with excellent internal consistency (α = 0.86 - 0.89), high test-retest reliability (0.84) and good criterion and construct validity and has been used extensively in populations with SCI.
Time to administer: 1 to 3 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
|
Change in General Anxiety Disorder 7-item (GAD-7)
Time Frame: Baseline, 6 weeks, 12 weeks, 18 weeks
|
The GAD-7 is a brief 7 item measure that will be used to assess the severity of general anxiety.
Using a four point Likert scale ranging from 0 (not at all sure) to 3 (nearly every day), respondents rate how often they have been bothered by specific symptoms during the past two weeks.
A total severity score, ranging from 0 to 21, is calculated by summing all items.
This measure has demonstrated high internal consistency (α = .89
- .92),
good test-retest reliability (icc = .83)
and adequate convergent and discriminant validity.
This scale has been used in previous studies involving persons with SCI.
Time to administer: 1 to 3 minutes.
|
Baseline, 6 weeks, 12 weeks, 18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jennifer Coker, MPH, Craig Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2959
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.